Quote Lookup

Please enter a ticker symbol below and click Submit.
Symbol:        VL Survey Page (2014-04-11)Premium Content

Biogen Idec Inc. (BIIB)

2014-04-17@00:35:45 ET
Biogen Idec to Report Clinical Data from Its Neurology Portfolio at AAN Annual Meeting (CLM)

2014-04-16@17:04:47 ET
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 2.10% Gain (PSM)

2014-04-16@17:04:16 ET
Biogen Idec Rises 2.10% on Heavy Volume: Watch For Potential Pullback (PSM)

2014-04-16@12:00:42 ET
Biogen Idec Bullish Moving Average Crossover Alert (BIIB) (F78)

2014-04-16@10:34:04 ET
Potential Biogen Idec (BIIB) Trade Has 8.34% Downside Protection (FBM)

2014-04-15@13:00:00 ET
Surveyed European Neurologists Expect to Prescribe Biogen Idec's Tecfidera to 16 Percent of their Diagnosed Relapsing-Remitting Multiple Sclerosis Patients in the Next 12 Months (PRN)

2014-04-15@08:36:46 ET
Biogen Idec (BIIB) Trading Near $267.85 Support Level (FBM)

2014-04-14@11:55:45 ET
Stock Investors Bid Up Shares of Biogen Idec, Up 2.0% (F77)

2014-04-14@10:27:50 ET
Biogen Idec Shares Down 10.1% Since SmarTrend's Sell Call (BIIB) (PSM)

2014-04-14@09:46:09 ET
Biogen Idec appoints senior vice president and chief strategy officer (DTM)

2014-04-14@09:45:57 ET
Biogen and Sobi announce positive results from Phase III hemophilia A study (DTM)

2014-04-14@07:30:27 ET
Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio at AAN Annual Meeting (BIZ)

2014-04-14@05:31:04 ET
R&D Expert Hosts Webinar on Lab Scale Manufacturing Using Continuous Crystallization (PRW)

2014-04-14@00:09:22 ET
Biogen Idec and Sobi Report Positive Top-Line Efficacy and Safety Results from Phase 3 Pediatric Study of Eloctate (CLM)

2014-04-11@16:52:09 ET
Watch for Biogen Idec to Potentially Rebound After Falling 4.65% Yesterday (PSM)

2014-04-11@16:51:37 ET
Biogen Idec Falls 4.65% on Heavy Volume: Watch For Potential Rebound (PSM)

2014-04-11@14:43:23 ET
Biogen Idec (BIIB) Showing Bearish Technicals With Resistance At $307.28 (FBM)

2014-04-11@09:00:28 ET
Pfizer's Ian Read Becomes PhRMA Board Chairman; Ken Frazier, George Scangos Assume New Posts (BIZ)